Skip to content
10-Q

Quarterly Report

TherapeuticsMD, Inc. TXMD

0001213900-25-075003

← back to feed
Filed
Aug 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 6, 2025 11.57M sh
Shares Diluted Q2 2025 · Jun 30, 2025 11.57M sh
Shares Diluted Q2 2025 · Jun 30, 2025 11.56M sh
Shares Diluted Q2 2025 · Jun 30, 2024 11.53M sh
Shares Diluted Q2 2025 · Jun 30, 2024 11.53M sh
Stockholders Equity Q2 2025 · Jun 30, 2025 $27.29M
Stockholders Equity Q2 2025 · Mar 31, 2025 $26.74M
Stockholders Equity Q2 2025 · Dec 31, 2024 $27.37M
Stockholders Equity Q2 2025 · Jun 30, 2024 $27.67M
Stockholders Equity Q2 2025 · Mar 31, 2024 $28.66M
Stockholders Equity Q2 2025 · Dec 31, 2023 $29.29M
Current Liabilities Q2 2025 · Jun 30, 2025 $4.66M
Current Liabilities Q2 2025 · Dec 31, 2024 $5.17M
Total Liabilities Q2 2025 · Jun 30, 2025 $11.21M
Total Liabilities Q2 2025 · Dec 31, 2024 $11.45M
Current Assets Q2 2025 · Jun 30, 2025 $13.46M
Current Assets Q2 2025 · Dec 31, 2024 $12.26M
Total Assets Q2 2025 · Jun 30, 2025 $38.5M
Total Assets Q2 2025 · Dec 31, 2024 $38.82M
Eps Diluted Q2 2025 · Jun 30, 2025 $0.05
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.01
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.09
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.16
Eps Basic Q2 2025 · Jun 30, 2025 $0.05
Eps Basic Q2 2025 · Jun 30, 2025 −$0.01
Eps Basic Q2 2025 · Jun 30, 2024 −$0.09
Eps Basic Q2 2025 · Jun 30, 2024 −$0.16
Sga Expense Q2 2025 · Jun 30, 2025 $1.55M
Sga Expense Q2 2025 · Jun 30, 2025 $3.04M
Sga Expense restated Q2 2025 · Jun 30, 2024 $1.58M
Sga Expense restated Q2 2025 · Jun 30, 2024 $3.3M
Net Income Q2 2025 · Jun 30, 2025 $551K
Net Income Q2 2025 · Jun 30, 2025 −$102K
Net Income Q2 2025 · Mar 31, 2025 −$653K
Net Income Q2 2025 · Jun 30, 2024 −$1.09M
Net Income Q2 2025 · Jun 30, 2024 −$1.82M
Net Income Q2 2025 · Mar 31, 2024 −$734K
Operating Income Q2 2025 · Jun 30, 2025 −$695K
Operating Income Q2 2025 · Jun 30, 2025 −$1.98M
Operating Income restated Q2 2025 · Jun 30, 2024 −$2.79M
Operating Income restated Q2 2025 · Jun 30, 2024 −$4.33M